Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer
- 2 October 2007
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 11 (10) , 1287-1298
- https://doi.org/10.1517/14728222.11.10.1287
Abstract
TNF-α converting enzyme (TACE/ADAM17) is a transmembrane metalloprotease that plays a key role in the cleavage and mobilization of receptor ligands that are initially synthesized as membrane-tethered precursors. For many years, attention has focused on the role of TACE-dependent TNF-α cleavage in arthritis and, more recently, it has become apparent that TACE also plays an important role in regulating epidermal growth factor receptor activity in several tumor types. This review presents the background to these findings and a rationale for the continued development of TACE inhibitors for the treatment of epidermal growth factor receptor-dependent epithelial tumors.Keywords
This publication has 89 references indexed in Scilit:
- Three-dimensional culture models of normal and malignant breast epithelial cellsNature Methods, 2007
- Matrix metalloproteinases and the regulation of tissue remodellingNature Reviews Molecular Cell Biology, 2007
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerBritish Journal of Cancer, 2006
- Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapyNature Reviews Cancer, 2006
- EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutationsLaboratory Investigation, 2005
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- EGFR and cancer prognosisPublished by Elsevier ,2001